{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:58:29Z","timestamp":1791673109765,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the exception of high-dose methotrexate (HD-MTX), there is currently no defined standard treatment for newly diagnosed primary central nervous system lymphoma (PCNSL). This review focused on first-line induction and consolidation treatment of PCNSL and aimed to determine the optimal combination of HD-MTX and the long-term beneficial consolidation methods. A comprehensive literature search of MEDLINE identified 1407 studies, among which 31 studies met the inclusion criteria. The meta-analysis was performed by using Stata SE version 15. Forest plots were generated to report combined outcomes like the complete response rate (CRR), overall survival, and progression-free survival. We also conducted univariate regression analyses of the baseline characteristics to identify the source of heterogeneity. Pooled analysis showed a CRR of 41% across all HD-MTX-based regimens, and three- and four-drug regimens had better CRRs than HD-MTX monotherapy. In all combinations based on HD-MTX, the HD-MTX\u2009+\u2009procarbazine\u2009+\u2009vincristine (MPV) regimen showed pooled CRRs of 63% and 58% with and without rituximab, respectively, followed by the rituximab\u2009+\u2009HD-MTX\u2009+\u2009temozolomide regimen, which showed a pooled CRR of 60%. Pooled PFS and OS showed that post-remission consolidation with autologous stem cell transplantation (ASCT) was associated with the best survival outcome, with a pooled 2-year OS of 80%, a 2-year PFS of 74%, a 5-year OS of 77%, and a 5-year PFS of 63%. Next, whole-brain radiation therapy (WBRT)\u2009+\u2009chemotherapy showed a pooled 2-year OS of 72%, 2-year PFS of 56%, 5-year OS of 55%, and 5-year PFS of 41%, with no detectable\u00a0CR heterogeneity throughout the entire treatment process. In HD-MTX-based therapy of newly diagnosed PCNSL, MPV with or without rituximab can be chosen as the inductive regimen, and the rituximab\u2009+\u2009HD-MTX\u2009+\u2009temozolomide regimen is also a practical choice. Based on our study, high-dose chemotherapy supported by ASCT is an efficacious approach for consolidation. Consolidation with WBRT\u2009+\u2009chemotherapy can be another feasible approach.<\/jats:p>","DOI":"10.1038\/s41598-020-80724-0","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T11:40:00Z","timestamp":1611315600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials"],"prefix":"10.1038","volume":"11","author":[{"given":"Junyao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueshi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"issue":"21","key":"80724_CR1","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes, C. & DeAngelis, L. M. Primary CNS lymphoma. J. Clin. Oncol. 35(21), 2410\u20132418 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"80724_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.1996.14.2.556","volume":"14","author":"C Schultz","year":"1996","unstructured":"Schultz, C. et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J. Clin. Oncol. 14(2), 556\u2013564 (1996).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"80724_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0360-3016(98)00450-7","volume":"43","author":"BP O'Neill","year":"1999","unstructured":"O\u2019Neill, B. P. et al. Primary central nervous system non-Hodgkin\u2019s lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the north central cancer treatment group (NCCTG) study 86-72-52. Int. J. Radiat. Oncol. Biol. Phys. 43(3), 559\u2013563 (1999).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"80724_CR4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9","volume":"89","author":"GM Mead","year":"2000","unstructured":"Mead, G. M. et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89(6), 1359\u20131370 (2000).","journal-title":"Cancer"},{"issue":"6","key":"80724_CR5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","volume":"21","author":"T Batchelor","year":"2003","unstructured":"Batchelor, T. et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol. 21(6), 1044\u20131049 (2003).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"80724_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/01.wnl.0000300671.37279.0e","volume":"70","author":"ER Gerstner","year":"2008","unstructured":"Gerstner, E. R. et al. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 70(5), 401\u2013402 (2008).","journal-title":"Neurology"},{"issue":"6","key":"80724_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/ana.20495","volume":"57","author":"U Herrlinger","year":"2005","unstructured":"Herrlinger, U. et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann. Neurol. 57(6), 843\u2013847 (2005).","journal-title":"Ann. Neurol."},{"issue":"5","key":"80724_CR8","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri, A. J. et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematol. 3(5), e217\u2013e227 (2016).","journal-title":"Lancet Haematol."},{"issue":"9700","key":"80724_CR9","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri, A. J. et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374(9700), 1512\u20131520 (2009).","journal-title":"Lancet"},{"issue":"1","key":"80724_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","volume":"23","author":"DF Nelson","year":"1992","unstructured":"Nelson, D. F. et al. Non-Hodgkin\u2019s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 23(1), 9\u201317 (1992).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"80724_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11060-018-2970-x","volume":"140","author":"J Wu","year":"2018","unstructured":"Wu, J. et al. Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. J. Neurooncol. 140(2), 427\u2013434 (2018).","journal-title":"J. Neurooncol."},{"issue":"9","key":"80724_CR12","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro, A. et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125(9), 1403\u20131410 (2015).","journal-title":"Blood"},{"issue":"8","key":"80724_CR13","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","volume":"3","author":"G Illerhaus","year":"2016","unstructured":"Illerhaus, G. et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 3(8), e388\u2013e397 (2016).","journal-title":"Lancet Haematol."},{"issue":"7","key":"80724_CR14","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","volume":"16","author":"K Hoang-Xuan","year":"2015","unstructured":"Hoang-Xuan, K. et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 16(7), e322\u2013e332 (2015).","journal-title":"Lancet Oncol."},{"issue":"11","key":"80724_CR15","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri, A. J. M. et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol. 4(11), e510\u2013e523 (2017).","journal-title":"Lancet Haematol."},{"issue":"2","key":"80724_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000055310","volume":"60","author":"AJ Ferreri","year":"2001","unstructured":"Ferreri, A. J. et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology 60(2), 134\u2013140 (2001).","journal-title":"Oncology"},{"issue":"17","key":"80724_CR17","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","volume":"18","author":"LE Abrey","year":"2000","unstructured":"Abrey, L. E., Yahalom, J. & DeAngelis, L. M. Treatment for primary CNS lymphoma: the next step. J. Clin. Oncol. 18(17), 3144\u20133150 (2000).","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"80724_CR18","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","volume":"21","author":"LE Abrey","year":"2003","unstructured":"Abrey, L. E. et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J. Clin. Oncol. 21(22), 4151\u20134156 (2003).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"80724_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11060-018-2856-y","volume":"139","author":"N Adhikari","year":"2018","unstructured":"Adhikari, N. et al. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome. J. Neurooncol. 139(1), 153\u2013166 (2018).","journal-title":"J. Neurooncol."},{"issue":"4","key":"80724_CR20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","volume":"10","author":"LM DeAngelis","year":"1992","unstructured":"DeAngelis, L. M. et al. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 10(4), 635\u2013643 (1992).","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"80724_CR21","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","volume":"20","author":"LM DeAngelis","year":"2002","unstructured":"DeAngelis, L. M. et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10. J. Clin. Oncol. 20(24), 4643\u20134648 (2002).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"80724_CR22","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1212\/01.wnl.0000210464.94122.e1","volume":"66","author":"AJ Ferreri","year":"2006","unstructured":"Ferreri, A. J. et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 66(9), 1435\u20131438 (2006).","journal-title":"Neurology"},{"issue":"2","key":"80724_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3171\/jns.1994.81.2.0188","volume":"81","author":"J Glass","year":"1994","unstructured":"Glass, J. et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J. Neurosurg. 81(2), 188\u2013195 (1994).","journal-title":"J. Neurosurg."},{"issue":"14","key":"80724_CR24","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","volume":"34","author":"J Glass","year":"2016","unstructured":"Glass, J. et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. J. Clin. Oncol. 34(14), 1620\u20131625 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"80724_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.10102","volume":"51","author":"U Herrlinger","year":"2002","unstructured":"Herrlinger, U. et al. German cancer society neuro-oncology working group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann. Neurol. 51(2), 247\u2013252 (2002).","journal-title":"Ann. Neurol."},{"issue":"24","key":"80724_CR26","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","volume":"24","author":"G Illerhaus","year":"2006","unstructured":"Illerhaus, G. et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J. Clin. Oncol. 24(24), 3865\u20133870 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"80724_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2141.2004.05284.x","volume":"128","author":"A Korfel","year":"2005","unstructured":"Korfel, A. et al. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br. J. Haematol. 128(2), 177\u2013183 (2005).","journal-title":"Br. J. Haematol."},{"issue":"4","key":"80724_CR28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/annonc\/mdl458","volume":"18","author":"M Montemurro","year":"2007","unstructured":"Montemurro, M. et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan\/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter ostdeutsche studiengruppe hamato-onkologie OSHO-53 phase II study. Ann. Oncol. 18(4), 665\u2013671 (2007).","journal-title":"Ann. Oncol."},{"issue":"31","key":"80724_CR29","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris, P. G. et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J. Clin. Oncol. 31(31), 3971\u20133979 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"80724_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1200\/JCO.2000.18.3.519","volume":"18","author":"P O'Brien","year":"2000","unstructured":"O\u2019Brien, P. et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J. Clin. Oncol. 18(3), 519\u2013526 (2000).","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"80724_CR31","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","volume":"21","author":"H Pels","year":"2003","unstructured":"Pels, H. et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J. Clin. Oncol. 21(24), 4489\u20134495 (2003).","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"80724_CR32","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","volume":"21","author":"PM Poortmans","year":"2003","unstructured":"Poortmans, P. M. et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European organization for research and treatment of cancer lymphoma group phase II trial 20962. J. Clin. Oncol. 21(24), 4483\u20134488 (2003).","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"80724_CR33","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein, J. L. et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J. Clin. Oncol. 31(25), 3061\u20133068 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"80724_CR34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","volume":"20","author":"JEC Bromberg","year":"2019","unstructured":"Bromberg, J. E. C. et al. Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 20(2), 216\u2013228 (2019).","journal-title":"Lancet Oncol."},{"issue":"11","key":"80724_CR35","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel, E. et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 11(11), 1036\u20131047 (2010).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80724-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80724-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80724-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:36:29Z","timestamp":1670034989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80724-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80724"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80724-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"25 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2125"}}